Definitive Healthcare Q3 Revenue $54.7M, Down 9%; Profit Beats, No Guidance on Advent Deal
DH sits 85% above its 52-week low of $0.61.
Summary
Definitive Healthcare posted Q3 revenue of $54.7M (down 9%) with Adjusted EBITDA of $15.7M, but gave no guidance and held no call while Advent's $1.02/share take-private proposal is pending.
Updates
· Reuters — Q3 revenue fell 9% yr/yr to $54.65 mln, slightly beating the $54.59 mln consensus estimate from 5 analysts.
- Q3 Profitability — Q3 gross profit was $42.23 mln, with a pretax loss of $5.91 mln and a net loss of $5.41 mln.
- Adjusted Net Income — Adjusted net income declined compared to the prior year.
All 4 details
- Q3 gross profit was $42.23 mln
- Q3 pretax loss was $5.91 mln
- Adjusted net income declined compared to the prior year
- Q3 net loss $5.41 mln
Key Events · Earnings and Guidance · DH
-
Q3 Revenue Falls 9% to $54.7M
Revenue came in at $54.7 million, down 9% from $60.0 million in Q3 2025, within the guidance range.
-
Profitability Holds on Adjusted Basis
Adjusted EBITDA was $15.7 million (29% of revenue) and Adjusted Net Income was $8.8 million, or $0.06 per diluted share; the net loss narrowed to $(5.4) million from $(17.8) million a year ago.
-
Cash Generation Remains Solid
Cash flow from operations was $11.4 million and Unlevered Free Cash Flow was $13.0 million in the quarter, leaving cash and equivalents of $177.1 million at September 30, 2026.
-
No Guidance or Call on Advent Deal
Citing the September 2, 2026 non-binding indication of interest from Advent International, the company will not provide financial guidance or host a conference call for Q3 2026.
Analysis · DH · Technology
Revenue fell 9% to $54.7M, yet the company stayed solidly profitable on an adjusted basis, with Adjusted EBITDA of $15.7M (29% of revenue) and $13.0M of unlevered free cash flow. What matters more is what's missing: management withheld guidance and skipped the earnings call because Advent International's $1.02-per-share take-private proposal is still pending. The quarter thus serves as a status check on the business rather than a forward-looking update, and the stock now trades on deal probability, not on these numbers.
How filings like this one have moved
In the 30 days to Nov 17, 2026, 38% of the 3791 measured filings Wiseek scored 7 moved their stock by 5% or more by the next session's close. The median move was 0.00%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, DH was trading at $1.13 on NASDAQ in the Technology sector, with a market capitalization of approximately $163.7M. The 52-week trading range was $0.61 to $3.00. This filing was assessed with neutral market sentiment and an importance score of 7 out of 10.